Mechanisms underlying the metabolic actions of galegine that contribute to weight loss in mice
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Background and purpose: Galegine and guanidine, originally isolated from Galega officinalis, led to the development of the biguanides. The weight‐reducing effects of galegine have not previously been studied and the present investigation was undertaken to determine its mechanism(s) of action. Experimental approach: Body weight and food intake were examined in mice. Glucose uptake and acetyl‐CoA carboxylase activity were studied in 3T3‐L1 adipocytes and L6 myotubes and AMP activated protein kinase (AMPK) activity was examined in cell lines. The gene expression of some enzymes involved in fat metabolism was examined in 3T3‐L1 adipocytes. Key results: Galegine administered in the diet reduced body weight in mice. Pair‐feeding indicated that at least part of this effect was independent of reduced food intake. In 3T3‐L1 adipocytes and L6 myotubes, galegine (50 μ M‐3 m M) stimulated glucose uptake. Galegine (1–300 μ M) also reduced isoprenaline‐mediated lipolysis in 3T3‐L1 adipocytes and inhibited acetyl‐CoA carboxylase activity in 3T3‐L1 adipocytes and L6 myotubes. Galegine (500 μ M) down‐regulated genes concerned with fatty acid synthesis, including fatty acid synthase and its upstream regulator SREBP. Galegine (10 μ M and above) produced a concentration‐dependent activation of AMP activated protein kinase (AMPK) in H4IIE rat hepatoma, HEK293 human kidney cells, 3T3‐L1 adipocytes and L6 myotubes. Conclusions and implications: Activation of AMPK can explain many of the effects of galegine, including enhanced glucose uptake and inhibition of acetyl‐CoA carboxylase. Inhibition of acetyl‐CoA carboxylase both inhibits fatty acid synthesis and stimulates fatty acid oxidation, and this may to contribute to the in vivo effect of galegine on body weight. British Journal of Pharmacology (2008) 153, 1669–1677; doi:10.1038/bjp.2008.37; published online 25 February 2008
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
OWEN, M. R., DORAN, E., & HALESTRAP, A. P. (2000) · Biochemical Journal · doi:10.1042/bj3480607 · Cited by 2,157 · cited 2×
“The effects of biguanides on AMPK are probably mediated by their ability to inhibit complex I of the respiratory chain (El-Mir et al., 2000; Owen et al., 2000), and thus increase the cellular AMP:ATP ratio.”
BackgroundThe Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950
Hawley, S. A., Pan, D. A., Mustard, K. J., Ross, L., Bain, J., Edelman, A. M., Frenguelli, B. G., & Hardie, D. G. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.05.009 · Cited by 1,589 · cited 1×
“Increases in AMP:ATP have indeed been demonstrated for phenformin (Hawley et al., 2005), although they have been more difficult to demonstrate for the less potent biguanide, metformin.”
BackgroundSelf-citationEl-Mir, M.-Y., Nogueira, V., Fontaine, E., Avéret, N., Rigoulet, M., & Leverve, X. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.223 · Cited by 1,399 · cited 2×
“The effects of biguanides on AMPK are probably mediated by their ability to inhibit complex I of the respiratory chain (El-Mir et al., 2000; Owen et al., 2000), and thus increase the cellular AMP:ATP ratio.”
BackgroundZong, H., Ren, J. M., Young, L. H., Pypaert, M., Mu, J., Birnbaum, M. J., & Shulman, G. I. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.252625599 · Cited by 1,036
Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2
Abu-Elheiga, L., Matzuk, M. M., Abo-Hashema, K. A. H., & Wakil, S. J. (2001) · Science · doi:10.1126/science.1056843 · Cited by 903
Hayashi, T., Hirshman, M. F., Kurth, E. J., Winder, W. W., & Goodyear, L. J. (1998) · Diabetes · doi:10.2337/diabetes.47.8.1369 · Cited by 774
Pasquali, R., Gambineri, A., Biscotti, D., Vicennati, V., Gagliardi, L., Colitta, D., Fiorini, S., Cognigni, G. E., Filicori, M., & Morselli-Labate, A. M. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.8.6738 · Cited by 635 · cited 2×
“This has already been proposed for the biguanides (Zhou et al., 2001; Hawley et al., 2002) which, like galegine, have been found to have an anti-obesity action (Pasquali et al., 2000; Kay et al., 2001; Kim et al., 2006).”
BackgroundInvolvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin
Wang, D.-S., Jonker, J. W., Kato, Y., Kusuhara, H., Schinkel, A. H., & Sugiyama, Y. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.034140 · Cited by 441 · cited 1×
“The effects of metformin in vivo appear to be primarily on the liver, possibly because hepatocytes express high levels of the organic cation transport, OCT1, which appears to facilitate the uptake of metformin (Wang et al., 2002; Shu et al., 2007).”
BackgroundWinder, W. W., Wilson, H. A., Hardie, D. G., Rasmussen, B. B., Hutber, C. A., Call, G. B., Clayton, R. D., Conley, L. M., Yoon, S., & Zhou, B. (1997) · Journal of Applied Physiology · doi:10.1152/jappl.1997.82.1.219 · Cited by 237
Self-citationSemple, R. K., Crowley, V. C., Sewter, C. P., Laudes, M., Christodoulides, C., Considine, R. V., Vidal-Puig, A., & O'Rahilly, S. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802482 · Cited by 203
Kim, W., Botchkarev, A. E., Salvador, A., Popovici, G., Tang, H., & Morkoç, H. (1997) · Journal of Applied Physics · doi:10.1063/1.365801 · Cited by 168
Yamaguchi, S., Katahira, H., Ozawa, S., Nakamichi, Y., Tanaka, T., Shimoyama, T., Takahashi, K., Yoshimoto, K., Imaizumi, M. O., Nagamatsu, S., et al. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00456.2004 · Cited by 141 · cited 1×
“There is considerable evidence that the effects of AICAR in stimulating glucose uptake involve glucose transporters (KurthKraczek et al., 1999; Yamaguchi et al., 2005), as suggested in the present study for galegine.”
Background
Cited by
AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function
Hardie, D. G. (2011) · Genes & Development · doi:10.1101/gad.17420111 · Cited by 1,638
Self-citationUse of Cells Expressing γ Subunit Variants to Identify Diverse Mechanisms of AMPK Activation
Hawley, S. A., Ross, F. A., Chevtzoff, C., Green, K. A., Evans, A., Fogarty, S., Towler, M. C., Brown, L. J., Ogunbayo, O. A., Evans, A. M., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.04.001 · Cited by 773
“, 2003), and a related natural product, galegine (Mooney et al., 2008); (3) another class of antidiabetic drug, the thiazolidinediones, (Fryer et al.”
BackgroundSelf-citationViollet, B., Guigas, B., Leclerc, J., Hébrard, S., Lantier, L., Mounier, R., Andreelli, F., & Foretz, M. (2009) · Acta Physiologica · doi:10.1111/j.1748-1716.2009.01970.x · Cited by 486
AMPK: A Target for Drugs and Natural Products With Effects on Both Diabetes and Cancer
Hardie, D. G. (2013) · Diabetes · doi:10.2337/db13-0368 · Cited by 458
“AMPK activation by metformin was indeed demonstrated in 2001 (36), and this was subsequently also shown for phenformin (13) and galegine (37).”
BackgroundSelf-citationAMP-Activated Protein Kinase: A Target for Drugs both Ancient and Modern
Hardie, D. G., Ross, F. A., & Hawley, S. A. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.08.019 · Cited by 372
Self-citation
Metadata
- Authors
- Mooney, M. H., Fogarty, S., Stevenson, C., Gallagher, A. M., Palit, P., Hawley, S. A., Hardie, D. G., Coxon, G. D., Waigh, R. D., Tate, R. J., Harvey, A. L., & Furman, B. L.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2008-04
- Volume
- 153
- Issue
- 8
- Pages
- 1669-1677
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2028843992
- Cited by
- 67
- References
- 13
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.